Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt's Lymphoma

被引:0
|
作者
Jaffari, Syed Muhammad Ibne Ali [1 ]
Hashmi, Masooma [2 ]
Hashmi, Abdul Wasey [1 ]
Nisar, Samaha [1 ]
Ashraf, Hafsa [1 ]
Tariq, Ghufran [3 ]
Farooq, Arslan [4 ]
Awan, Javeria [5 ]
Zaidi, Wasey Syed Muhammad Jawad [6 ,7 ]
Kaneez, Mehwish [6 ,7 ]
机构
[1] Shalamar Med & Dent Coll, Pediat, Lahore, Pakistan
[2] Royal Wolverhampton NHS Trust, Walsall Manor Hosp, Internal Med, Walsall, England
[3] Arif Mem Teaching Hosp, Pediat, Lahore, Pakistan
[4] Combined Mil Hosp, Internal Med, Lahore, Pakistan
[5] Rawalpindi Med Univ, Pediat, Rawalpindi, Pakistan
[6] Holy Family Hosp, Pediat, Rawalpindi, Pakistan
[7] Shaukat Khanum Mem Canc Hosp & Res Ctr, Pediat Oncol, Lahore, Pakistan
关键词
Categories; Pediatrics; Disease; Oncology bacterial infections; induction chemotherapy; infection-associated mortality; intermediate risk; burkitt's lymphoma; MIDDLE-INCOME COUNTRIES; CHILDHOOD-CANCER; CHILDREN; EXPERIENCE; MANAGEMENT;
D O I
10.7759/cureus.40365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan.Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children's Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed.Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 & PLUSMN; 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Preliminary results of a phase II study of chemoimmunotherapy (rituximab plus FAB chemotherapy) in children and adolescents with intermediate risk B-cell NHL: A children's oncology group report
    Goldman, S.
    Lynch, J.
    Davenport, V.
    Perkins, S.
    Shiramizu, B.
    Sanger, W.
    Gross, T.
    Harrison, L.
    Bancroft, M.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 110
  • [42] Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt's lymphoma during rituximab-containing treatments: a case report
    Xue, Xuemin
    Fu, Libing
    Qiu, Tian
    Cao, Zheng
    Wang, Xiaojun
    Rao, Wei
    Luo, Yiyang
    He, Lejian
    Feng, Xiaoli
    VIRCHOWS ARCHIV, 2023, 483 (01) : 111 - 116
  • [43] Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt’s lymphoma during rituximab-containing treatments: a case report
    Xuemin Xue
    Libing Fu
    Tian Qiu
    Zheng Cao
    Xiaojun Wang
    Wei Rao
    Yiyang Luo
    Lejian He
    Xiaoli Feng
    Virchows Archiv, 2023, 483 : 111 - 116
  • [44] The Interim Results of the Significance of Upfront High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IV Stage and High-Intermediate/High Risk Groups of Diffuse Large B-Cell Lymphoma with Complete Response after Induction Chemotherapy
    Koviazin, Aleksei
    Filatova, Larisa
    Zyuzgin, Ilya
    Artemyeva, Anna
    Motalkina, Margarita
    Chudinovskikh, Yulia
    Volchenkov, Stanislav
    Poliatskin, Ilia
    Cherkasova, Evgeniya
    Shalaev, Sergey
    Ishmatova, Irina
    Zverkova, Anna
    Ghanzin, Maksim
    Burda, Darya
    Semiglazova, Tatiana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S385 - S385
  • [45] Risk-Adapted Therapy with ABVD for Low- and Intermediate-Risk Patients and Oepa-Copdac for High Risk Patients Plus Involved-Field Radiation Therapy (IFRT) Based on Prognosis at Diagnosis and Early Response: Results from Pediatric Argentinian Collaborative Group Gatla Study for Children and Adolescents with Hodgkin Lymphoma
    Veron, David Alejandro
    Streitenberger, Patricia
    Riccheri, Cecilia
    Matus, Monica
    Aranguren, Pedro Negri
    Costa, Maria Alejandra
    Rossi, Nestor Alfredo
    Hiramatsu, Elizabeth
    Cedola, Maria Alejandra
    Drozdowski, Maria Constanza
    Borchichi, Sandra
    Coirini, Marcelo
    Murray, Maria Cecilia
    D'Aloi, Karina
    Holmann, Carlos
    Gomel, Matilde
    Drago, Gisela
    Caferri, Horacio Daniel
    Barbieri, Maria Angelica Fernandez
    Villamil, Mara
    Ruiz, Claudia Mabel
    Zirone, Sandra Ethel
    Makiya, Monica
    BLOOD, 2020, 136
  • [46] Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance
    O'Leary, Ashley L.
    Wattengel, Bethany A.
    Carter, Michael T.
    Drye, Alexandra F.
    Mergenhagen, Kari A.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2023, 51 (06) : 603 - 606
  • [47] Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies
    White, Deborah L.
    Rehn, Jacqueline A.
    Schutz, Caitlin E.
    Heatley, Susan L.
    Eadie, Laura N.
    Thomson, Ashlee
    Page, Elyse C.
    Osborn, Michael
    Gangatharan, Shane
    Ng, Ashley P.
    Fleming, Shaun
    Fedele, Pasquale
    Trahair, Toby
    Casey, John
    Mapp, Sally
    Cheung, Carol C. Y.
    Armytage, Tasman
    Henderson, Michelle
    Sutton, Rosemary
    Larsen, Stephen Robert
    Presgrave, Peter
    Kwan, John
    Bennett, Samuel
    Fong, Chun Yew
    Dalla-Pozza, Luciano
    Yeung, David T.
    Greenwood, Matthew
    BLOOD, 2023, 142
  • [48] Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study
    Parsons, Susan K.
    Rodday, Angie Mae
    Pei, Qinglin
    Keller, Frank G.
    Wu, Yue
    Henderson, Tara O.
    Cella, David
    Kelly, Kara M.
    Castellino, Sharon M.
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2023, 7 (01)
  • [49] Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study
    Susan K. Parsons
    Angie Mae Rodday
    Qinglin Pei
    Frank G. Keller
    Yue Wu
    Tara O. Henderson
    David Cella
    Kara M. Kelly
    Sharon M. Castellino
    Journal of Patient-Reported Outcomes, 7
  • [50] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48